Advances in Thiopurine Drug Delivery: The Current State-of-the-Art

Area of Science:

• Pharmacology and Drug Delivery

Background:

• Thiopurines (mercaptopurine, azathioprine, thioguanine) are essential maintenance therapies for leukemia, inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and other autoimmune conditions.
• Current thiopurine use is constrained by significant off-target toxicities, including myelotoxicity and hepatotoxicity, affecting millions of patients globally.
• Enhancing targeted thiopurine efficacy through advanced delivery systems and pharmacogenetic testing is a critical area of research.

Purpose of the Study:

• To review and overview novel drug delivery strategies for thiopurine medications.
• To focus on advancements in modified-release and nano-based formulations for thiopurines.

Main Methods:

• Review of existing literature on controlled-release thiopurine formulations.
• Analysis of recent pre-clinical data on nano-formulations of thiopurines.
• Synthesis of findings on modified-release and nano-based drug delivery systems.

Main Results:

• Controlled-release thiopurine formulations have demonstrated promising clinical outcomes, particularly in inflammatory bowel disease.
• Emerging nano-formulations show encouraging pre-clinical results for thiopurines, suggesting potential for improved therapeutic profiles.
• Further research and development are necessary to translate nano-formulation potential into clinical applications.

Conclusions:

• Novel drug delivery systems, including modified-release and nano-formulations, offer promising avenues to enhance thiopurine therapy.
• These strategies aim to improve treatment efficacy and mitigate the dose-limiting toxicities associated with conventional thiopurine administration.
• Continued investigation into these advanced delivery methods is crucial for optimizing thiopurine-based treatments for various diseases.